Univariate analysis of potential prognostic factors for EFS, PFS, CSS, and OS in the patients treated in the randomized IELSG-19 study
| Parameter . | Group (N) . | EFS . | PFS . | CSS . | OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-y rate, % (95% CIs) . | Median, y . | P . | 5-y rate, % (95% CIs) . | Median, y . | P . | 5-y rate, % (95% CI) . | Median, y . | P . | 5-y rate, % (95% CI) . | Median, y . | P . | ||
| Age ≥70 y | Yes (92) | 43.1 (32.8-53.0) | 3.4 | .0002 | 67.4 (61.5-72.5) | NR | .0001 | 86.6 (77.1-92.4) | NR | <.0001 | 68.5 (57.6-77.1) | 9.1 | <.0001 |
| No (309) | 60.9 (55.1-66.1) | 9.8 | 55.8 (44.8-65.4) | 4.6 | 99.6 (97.6-99.9) | NR | 96.9 (94.1-98.4) | NR | |||||
| Male sex | Yes (197) | 54.6 (47.2-61.3) | 7.4 | .3403 | 60.4 (52.8-67.1) | 9.1 | .3074 | 96.6 (92.6-98.5) | NR | .7256 | 89.7 (84.3-93.3) | NR | .8342 |
| No (204) | 58.8 (51.7-65.3) | 9.8 | 62.2 (57.9-71.6) | NR | 96.9 (93.3-98.6) | NR | 90.1 (85.9-94.2) | NR | |||||
| B symptoms | Yes (42) | 50.7 (34.5-64.9) | 7.4 | .1922 | 55.3 (38.1-69.6) | 7.4 | .1567 | 86.5 (70.5-94.2) | NR | .0028 | 80.0 (63.9-89.5) | NR | .0125 |
| No (359) | 57.5 (52.1-62.4) | 8.6 | 63.7 (58.2-68.6) | NR | 97.9 (95.6-99.0) | NR | 91.5 (88.0-94.0) | NR | |||||
| ECOG PS ≥ 2 | Yes (6) | 16.7 (0.8-51.7) | 0.8 | .0277 | 16.7 (0.7-51.7) | 1.4 | .0046 | 80.0 (20.4-96.9) | 5.4 | <.0001 | 66.7 (19.5-94.4) | 5.3 | <.0001 |
| No (395) | 57.3 (52.2-62.1) | 8.6 | 63.6 (58.4-68.4) | NR | 97.0 (94.7-98.3) | NR | 90.7 (87.2-93.2) | NR | |||||
| β2MG >UNL | Yes (46) | 43.2 (28.7-56.9) | 3.9 | .0315 | 48.0 (32.3-62.0) | 4.9 | .0296 | 90.8 (77.2-96.4) | NR | .0084 | 82.5 (68.1-90.8) | NR | .0010 |
| No (243) | 60.7 (54.2-66.6) | 9.6 | 66.6 (60.0-72.4) | NR | 98.3 (95.5-99.3) | NR | 93.5 (89.5-96.0) | NR | |||||
| LDH >UNL | Yes (42) | 35.6 (21.6-49.9) | 1.9 | .0004 | 41.2 (25.8-56.0) | 2.4 | .0001 | 92.3 (78.0-97.5) | NR | .0071 | 80.3 (64.4-89.6) | NR | .0087 |
| No (358) | 59.4 (54.0-64.4) | 9.6 | 65.6 (60.2-70.5) | NR | 97.3 (94.9-98.6) | NR | 91.7 (88.3-94.2) | NR | |||||
| Stage III-IV | Yes (175) | 44.2 (36.7-51.5) | 3.5 | <.0001 | 49.6 (41.5-57.1) | 4.9 | <.0001 | 94.4 (89.4-97.0) | NR | .0070 | 84.5 (78.0-89.2) | NR | .0027 |
| No (226) | 66.5 (59.8-72.3) | NR | 73.2 (66.6-78.7) | NR | 98.6 (95.7-99.5) | NR | 94.8 (90.9-97.1) | NR | |||||
| Gastric localization | Yes (171) | 62.3 (54.4-69.2) | 10.1 | .0241 | 70.8 (62.9-77.3) | NR | .0013 | 98.1 (94.3-99.4) | NR | .198 | 93.1 (87.9-96.1) | NR | .0729 |
| No (230) | 52.6 (45.9-58.9) | 5.7 | 57.1 (50.1-63.5) | 7.0 | 95.8 (92.1-97.8) | NR | 88.3 (83.3-91.9) | NR | |||||
| Nodal involvement | Yes (142) | 45.7 (37.2-53.8) | 3.4 | .0001 | 51.2 (42.1-59.5) | 5.6 | <.0001 | 95.2 (89.7-97.8) | NR | .0465 | 85.1 (77.8-90.1) | NR | .0385 |
| No (259) | 62.7 (56.4-68.3) | NR | 69.2 (62.8-74.6) | NR | 97.6 (94.7-98.9) | NR | 93.1 (89.2-95.7) | NR | |||||
| Extranodal sites >1 | Yes (123) | 48.5 (39.3-57.1) | 4.3 | .0157 | 52.3 (42.8-61.0) | 5.7 | .0022 | 93.7 (87.3-97.0) | NR | .0474 | 83.7 (75.6-89.3) | NR | .0035 |
| No (278) | 60.3 (54.2-65.9) | 9.6 | 67.7 (61.5-73.1) | NR | 98.1 (95.4-99.2) | NR | 93.2 (89.4-95.7) | NR | |||||
| Parameter . | Group (N) . | EFS . | PFS . | CSS . | OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-y rate, % (95% CIs) . | Median, y . | P . | 5-y rate, % (95% CIs) . | Median, y . | P . | 5-y rate, % (95% CI) . | Median, y . | P . | 5-y rate, % (95% CI) . | Median, y . | P . | ||
| Age ≥70 y | Yes (92) | 43.1 (32.8-53.0) | 3.4 | .0002 | 67.4 (61.5-72.5) | NR | .0001 | 86.6 (77.1-92.4) | NR | <.0001 | 68.5 (57.6-77.1) | 9.1 | <.0001 |
| No (309) | 60.9 (55.1-66.1) | 9.8 | 55.8 (44.8-65.4) | 4.6 | 99.6 (97.6-99.9) | NR | 96.9 (94.1-98.4) | NR | |||||
| Male sex | Yes (197) | 54.6 (47.2-61.3) | 7.4 | .3403 | 60.4 (52.8-67.1) | 9.1 | .3074 | 96.6 (92.6-98.5) | NR | .7256 | 89.7 (84.3-93.3) | NR | .8342 |
| No (204) | 58.8 (51.7-65.3) | 9.8 | 62.2 (57.9-71.6) | NR | 96.9 (93.3-98.6) | NR | 90.1 (85.9-94.2) | NR | |||||
| B symptoms | Yes (42) | 50.7 (34.5-64.9) | 7.4 | .1922 | 55.3 (38.1-69.6) | 7.4 | .1567 | 86.5 (70.5-94.2) | NR | .0028 | 80.0 (63.9-89.5) | NR | .0125 |
| No (359) | 57.5 (52.1-62.4) | 8.6 | 63.7 (58.2-68.6) | NR | 97.9 (95.6-99.0) | NR | 91.5 (88.0-94.0) | NR | |||||
| ECOG PS ≥ 2 | Yes (6) | 16.7 (0.8-51.7) | 0.8 | .0277 | 16.7 (0.7-51.7) | 1.4 | .0046 | 80.0 (20.4-96.9) | 5.4 | <.0001 | 66.7 (19.5-94.4) | 5.3 | <.0001 |
| No (395) | 57.3 (52.2-62.1) | 8.6 | 63.6 (58.4-68.4) | NR | 97.0 (94.7-98.3) | NR | 90.7 (87.2-93.2) | NR | |||||
| β2MG >UNL | Yes (46) | 43.2 (28.7-56.9) | 3.9 | .0315 | 48.0 (32.3-62.0) | 4.9 | .0296 | 90.8 (77.2-96.4) | NR | .0084 | 82.5 (68.1-90.8) | NR | .0010 |
| No (243) | 60.7 (54.2-66.6) | 9.6 | 66.6 (60.0-72.4) | NR | 98.3 (95.5-99.3) | NR | 93.5 (89.5-96.0) | NR | |||||
| LDH >UNL | Yes (42) | 35.6 (21.6-49.9) | 1.9 | .0004 | 41.2 (25.8-56.0) | 2.4 | .0001 | 92.3 (78.0-97.5) | NR | .0071 | 80.3 (64.4-89.6) | NR | .0087 |
| No (358) | 59.4 (54.0-64.4) | 9.6 | 65.6 (60.2-70.5) | NR | 97.3 (94.9-98.6) | NR | 91.7 (88.3-94.2) | NR | |||||
| Stage III-IV | Yes (175) | 44.2 (36.7-51.5) | 3.5 | <.0001 | 49.6 (41.5-57.1) | 4.9 | <.0001 | 94.4 (89.4-97.0) | NR | .0070 | 84.5 (78.0-89.2) | NR | .0027 |
| No (226) | 66.5 (59.8-72.3) | NR | 73.2 (66.6-78.7) | NR | 98.6 (95.7-99.5) | NR | 94.8 (90.9-97.1) | NR | |||||
| Gastric localization | Yes (171) | 62.3 (54.4-69.2) | 10.1 | .0241 | 70.8 (62.9-77.3) | NR | .0013 | 98.1 (94.3-99.4) | NR | .198 | 93.1 (87.9-96.1) | NR | .0729 |
| No (230) | 52.6 (45.9-58.9) | 5.7 | 57.1 (50.1-63.5) | 7.0 | 95.8 (92.1-97.8) | NR | 88.3 (83.3-91.9) | NR | |||||
| Nodal involvement | Yes (142) | 45.7 (37.2-53.8) | 3.4 | .0001 | 51.2 (42.1-59.5) | 5.6 | <.0001 | 95.2 (89.7-97.8) | NR | .0465 | 85.1 (77.8-90.1) | NR | .0385 |
| No (259) | 62.7 (56.4-68.3) | NR | 69.2 (62.8-74.6) | NR | 97.6 (94.7-98.9) | NR | 93.1 (89.2-95.7) | NR | |||||
| Extranodal sites >1 | Yes (123) | 48.5 (39.3-57.1) | 4.3 | .0157 | 52.3 (42.8-61.0) | 5.7 | .0022 | 93.7 (87.3-97.0) | NR | .0474 | 83.7 (75.6-89.3) | NR | .0035 |
| No (278) | 60.3 (54.2-65.9) | 9.6 | 67.7 (61.5-73.1) | NR | 98.1 (95.4-99.2) | NR | 93.2 (89.4-95.7) | NR | |||||
β2-MG, serum β2 microglobulin; NR, not reached; UNL, upper normal limit.